Oncothyreon Inc (NASDAQ:ONTY)
| 2.00 Data as of May 21 |  0.00 / 0.00%Today’s Change | 1.71 Today|||52-Week Range 6.24 | +4.17% Year-to-Date |
Latest ONTY News | Press Releases
| ASCO '13 Preview: Oncothyreon's Failed Lung Cancer Vaccine May 15 / TheStreet.com |
Today’s Trading
| Previous close | 2.00 |
| Today’s open | 2.02 |
| Day’s range | -- - -- |
| Volume | 1,333,064 |
| Average volume (3 months) | 857,082 |
| Market cap | $114.4M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/21/2013
Growth & Valuation
| Earnings growth (last year) | +94.64% |
| Earnings growth (this year) | -856.21% |
| Earnings growth (next 5 years) | +0.20% |
| Revenue growth (last year) | -100.00% |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 1.39 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ENZEnzo Biochem Inc | +0.04 | +1.78% |
| BSTCBiospecifics Technol... | +0.13 | +0.83% |
| IMUCImmunoCellular Thera... | 0.00 | 0.00% |
| CDXSCodexis Inc | +0.03 | +1.48% |
Data as of 4:01pm ET, 05/21/2013
Financials
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -$0.14 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$3.4M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Robert L. Kirkman, MD |
Chief Operating Officer Gary Christianson |
Corporate headquarters Seattle, Washington |
Forecasts
